The Hereditary Angioedema Market: Trends, Share, Size, Growth, Opportunity And Forecast 2025

 

Hereditary angioedema (HAE) is a rare genetic condition characterized by recurrent episodes of nonpruritic, nonpitting, subcutaneous, and submucosal swelling with no urticarial lesions. Due to a blood protein deficiency, causes extreme pain, nausea, vomiting, diarrhea, fatigue, muscle ache, tingling, headache, belly pain, hoarseness, and mood changes. Fluid leakage occurs as a result of the constant accumulation of liquids outside the veins of the hands, feet, intestinal wall, genitals, face, tongue, and larynx. The demand for hereditary angioedema therapeutics is currently increasing due to global advancements in novel therapeutics.

Trends in the Hereditary Angioedema Therapeutics Market:

Due to a lack of C1 protein, there is currently a significant increase in the prevalence of HAE among individuals. As a result, there is an increase in global demand for the Hereditary AngioedemaMarket. This, along with increasing public awareness about HAE treatment, is one of the key factors driving the market. Furthermore, key market participants are heavily investing in research and development (R&D) activities to improve orphan drug development.

The hereditary Angioedema Market, combined with the rising demand for subcutaneous injections that are highly effective in administering medications such as insulin, morphine, diacetylmorphine, and goserelin, is propelling Hereditary Angioedema Market growth. Furthermore, governments in several countries are launching initiatives to facilitate faster diagnosis and provide patients with the best possible treatment and care. In line with this, the increasing prevalence of genetic mutations that cause the disorder is positively influencing the market. Aside from that, the rising demand for preventive medical care to avoid future illness and treatment presents lucrative growth opportunities for industry investors. Aside from that, the burgeoning healthcare industry is boosting the market growth.

CSL Behring, Shire Plc., Pharming Healthcare, Inc., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Adverum Biotechnologies, and Attune Pharmaceuticals, Inc. are some of the major players in the global hereditary angioedema market.